Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Ariad Pharmaceuticals Inc. (ARIA - Snapshot Report) recently announced that its tyrosine kinase inhibitor (TKI), Iclusig (ponatinib), has been granted marketing authorization in the EU by the European Commission (EC). Iclusig gained EU approval for two indications.

The first indication is the treatment of chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) in adults who do not respond to or cannot tolerate Sprycel (dasatinib) or Tasigna (nilotinib). It is also approved for patients in whom Gleevec (imatinib) is not appropriate as a subsequent treatment. The second indication covers the treatment of Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in adults unresponsive to Sprycel. It also includes patients for whom Gleevec is not clinically appropriate. Iclusig is also approved for patients who have the T315I mutation.

The most common serious adverse reactions found in Iclusig were pancreatitis, abdominal pain, pyrexia, anemia, febrile neutropenia, decrease in platelet count and neutrophil count, pancytopenia, myocardial infarction, diarrhea, and increased lipase. Meanwhile, the adverse reactions of any severity, which were most common (≥20%), were decrease in platelet count, rash, dry skin and abdominal pain.

EU approval was in line with expectations as the CHMP had rendered a positive opinion in Mar 2013.

Ariad gained US Food and Drug Administration (FDA) approval in Dec 2012 for Iclusig and launched it in Jan 2013. The drug gained approval for treating adults suffering from chronic, accelerated or blast phase chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to TKI therapy. Ariad recorded Iclusig sales of $6.4 million in the first quarter of 2013.

Ariad currently carries a Zacks Rank #3 (Hold). At present, companies like Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report), Santarus, Inc. and Salix Pharmaceuticals Ltd. (SLXP - Analyst Report) look well positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%